Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 6, 2026
March 6, 2026
616a1c25-5ddb-4458-88d6-d59f11231a76
Related Documents
Considerations in Demonstrating Interchangeability With a Reference Product: Update
Guidance DocumentJune 21, 2024Center for Drug Evaluation and Research
Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities
Guidance DocumentOctober 26, 2023Center for Drug Evaluation and Research
Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff
Guidance DocumentDecember 12, 2018Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.